GlassScriptPhysician profile
Nishant B Patel
NPI 1194962225
$7,951.41
in general payments reported to CMS, 2019-2025
37 companies · $967 in 2025
The $967 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $844 · 2020: $275 · 2021: $364 · 2022: $1,910 · 2023: $583 · 2024: $3,009 · 2025: $967.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,379 · Consulting Fee: $2,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,379.21 |
| Consulting Fee | $2,180.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,237.47 | 2019-2024 | |
| Abbott Laboratories | $1,784.23 | 2019-2024 | Cardiomems, Diamondback Peripheral |
| Boston Scientific Corporation | $1,029.15 | 2019-2025 | Watchman Access System, Avvigo Guidance System, Opticross 6 |
| Abiomed | $550.08 | 2019-2025 | Impella |
| Atricure, INC. | $248.26 | 2023-2025 | Atricure Cryoice Cryosphere Cryoablation System |
| Shockwave Medical, INC | $229.46 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $223.64 | 2019-2023 | Xarelto |
| Edwards Lifesciences Corporation | $186.83 | 2019-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Hemosphere, Sapien 3 Ultra Resilia |
| Inari Medical, INC. | $133.33 | 2019 | |
| Philips North America LLC | $107.18 | 2022 | |
| Biosense Webster, INC. | $93.31 | 2022-2025 | Nuvision Ice Catheter, Carto 3 |
| Gentuity, LLC | $90.64 | 2023 | Vis-Rx, Gentuity Hf-Oct Imaging System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $87.92 | 2019-2020 | |
| Impulse Dynamics (USA) INC. | $81.24 | 2023 | Optimizer |
| Recor Medical INC | $80.74 | 2025 | Paradise Ultrasound Renal Denervation System |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiva Medical, INC. | $72.67 | 2023-2025 | Cardiva Vascade 6/7f Vcs, Cardiva Vascade Mvp Xl Vvcs 10-12f |
| Cordis US Corp. | $63.22 | 2023-2025 | Rain Sheath Transradial, Mynx Control Venous, Stabilizer |
| Astrazeneca Pharmaceuticals LP | $57.04 | 2019-2024 | Farxiga |
| Kiniksa Pharmaceuticals International, Plc | $54.48 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.49 | 2019-2022 | |
| Novo Nordisk INC | $45.37 | 2025 | Rybelsus, Ozempic |
| Heartflow, INC. | $43.98 | 2024-2025 | |
| Medtronic, INC. | $42.38 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $40.33 | 2023 | Inpefa |
| Zoll Circulation INC | $38.87 | 2025 | Therox Ds2 Console, Downstream Cartridge, Catheter |
| E.R. Squibb & Sons, L.L.C. | $37.77 | 2022 | |
| Terumo Medical Corporation | $34.79 | 2019-2021 | |
| Teleflex LLC | $32.06 | 2025 | Guideliner, Supercross |
| Pfizer INC. | $31.68 | 2019-2021 | |
| Biotronik INC. | $25.38 | 2019-2020 | |
| Cook Medical LLC | $23.08 | 2025 | Neff |
| Ethicon US, LLC | $21.37 | 2019 | |
| Lilly USA, LLC | $19.67 | 2024 | Mounjaro |
| Medtronic Vascular, INC. | $19.60 | 2019 | |
| Getinge USA Sales, LLC | $19.40 | 2019 | |
| Ekos Corporation | $14.30 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nishant Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.